Literature DB >> 11290599

Primary human herpesvirus 8 infection generates a broadly specific CD8(+) T-cell response to viral lytic cycle proteins.

Q J Wang1, F J Jenkins, L P Jacobson, L A Kingsley, R D Day, Z W Zhang, Y X Meng, P E Pellett, K G Kousoulas, A Baghian, C R Rinaldo, P E Pellet.   

Abstract

Human herpesvirus 8 (HHV-8) is a recently discovered gammaherpesvirus that is the etiologic agent of Kaposi sarcoma (KS). The natural history of primary HHV-8 infection, including clinical outcome and host immune responses that may be important in preventing disease related to HHV-8, has not been elucidated. The present study characterized the clinical, immunologic, and virologic parameters of primary HHV-8 infection in 5 cases detected during a 15-year longitudinal study of 108 human immunodeficiency virus type 1 seronegative men in the Multicenter AIDS Cohort Study. Primary HHV-8 infection was associated with mild, nonspecific signs and symptoms of diarrhea, fatigue, localized rash, and lymphadenopathy. There were no alterations in numbers of CD4(+) or CD8(+) T cells or CD8(+) T-cell interferon gamma (IFN-gamma) production to mitogen or nominal antigen. CD8(+) cytotoxic T-lymphocyte precursor (CTLp) and IFN-gamma reactivity were detected during primary HHV-8 infection, with broad specificity to 5 lytic cycle proteins of HHV-8 encoded by open reading frame 8 (ORF 8; glycoprotein B homolog of Epstein-Barr virus), ORF 22 (gH homolog), ORF 25 (major capsid protein homolog), ORF 26 (a minor capsid protein homolog), or ORF 57 (an early protein homolog), in association with increases in serum antibody titers and appearance of HHV-8 DNA in blood mononuclear cells. CD8(+) T-cell responses to HHV-8 decreased by 2 to 3 years after primary infection. This antiviral T-cell response may control initial HHV-8 infection and prevent development of disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11290599     DOI: 10.1182/blood.v97.8.2366

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  30 in total

Review 1.  Herpesvirus infections in organ transplant recipients.

Authors:  Frank J Jenkins; David T Rowe; Charles R Rinaldo
Journal:  Clin Diagn Lab Immunol       Date:  2003-01

2.  Latent Kaposi's sarcoma-associated herpesvirus infection of monocytes downregulates expression of adaptive immune response costimulatory receptors and proinflammatory cytokines.

Authors:  Sean M Gregory; Ling Wang; John A West; Dirk P Dittmer; Blossom Damania
Journal:  J Virol       Date:  2012-01-25       Impact factor: 5.103

3.  Clinical presentation and outcome of epidemic Kaposi sarcoma in Ugandan children.

Authors:  Soren Gantt; Abel Kakuru; Anna Wald; Victoria Walusansa; Lawrence Corey; Corey Casper; Jackson Orem
Journal:  Pediatr Blood Cancer       Date:  2010-05       Impact factor: 3.167

4.  Herpes simplex virus type 2 (HSV-2) as a coronary atherosclerosis risk factor in HIV-infected men: multicenter AIDS cohort study.

Authors:  Rulin C Hechter; Matthew Budoff; Howard N Hodis; Charles R Rinaldo; Frank J Jenkins; Lisa P Jacobson; Lawrence A Kingsley; Babafemi Taiwo; Wendy S Post; Joseph B Margolick; Roger Detels
Journal:  Atherosclerosis       Date:  2012-03-14       Impact factor: 5.162

Review 5.  Human herpesviruses 6, 7, and 8 from a dermatologic perspective.

Authors:  Michael M Wolz; Gabriel F Sciallis; Mark R Pittelkow
Journal:  Mayo Clin Proc       Date:  2012-07-21       Impact factor: 7.616

6.  Identification of cytotoxic T lymphocyte epitopes of human herpesvirus 8.

Authors:  Fabiola Micheletti; Paolo Monini; Cinzia Fortini; Paola Rimessi; Martina Bazzaro; Massimo Andreoni; Massimo Giuliani; Serena Traniello; Barbara Ensoli; Riccardo Gavioli
Journal:  Immunology       Date:  2002-07       Impact factor: 7.397

7.  Surface downregulation of major histocompatibility complex class I, PE-CAM, and ICAM-1 following de novo infection of endothelial cells with Kaposi's sarcoma-associated herpesvirus.

Authors:  Costin Tomescu; Wai K Law; Dean H Kedes
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

8.  Chronic human herpes virus 8 infection successfully treated with valganciclovir.

Authors:  James J Yun; Veronica Preda; Brad Frankum
Journal:  World Allergy Organ J       Date:  2009-07       Impact factor: 4.084

9.  Cytokine production by human herpesvirus 8-infected dendritic cells.

Authors:  Heather R Hensler; Giovanna Rappocciolo; Charles R Rinaldo; Frank J Jenkins
Journal:  J Gen Virol       Date:  2009-01       Impact factor: 3.891

10.  Humanized-BLT mouse model of Kaposi's sarcoma-associated herpesvirus infection.

Authors:  Lin-Xu Wang; Guobin Kang; Pankaj Kumar; Wuxun Lu; Yue Li; You Zhou; Qingsheng Li; Charles Wood
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-10       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.